Immunicum AB (publ) today announced a clarification in response to several questions on Immunicum’s update on the HCC phase I/II study from April 23 concerning the number of patients who are still alive in the study. A total of 4 of the 9 recruited patients in the study are still alive, including one patient with bile duct cancer. Management is encouraged by the overall outcome in the HCC phase I/II study for the patients who received full vaccination. Four additional patients will be included in the study.
Read the press release here: Press release 150428 – HCC clarification
Notice: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4805